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Abstract: Malassezia spp. is a genus of lipophilic yeasts and comprises the most common 
fungi on healthy human skin. Despite its role as a commensal on healthy human skin, 
Malassezia spp. is attributed a pathogenic role in atopic dermatitis. The mechanisms by 
which Malassezia spp. may contribute to the pathogenesis of atopic dermatitis are not fully 
understood. Here, we review the latest findings on the pathogenetic role of Malassezia spp. 
in atopic dermatitis (AD). For example, Malassezia spp. produces a variety of immunogenic 
proteins that elicit the production of specific IgE antibodies and may induce the release of 
pro-inflammatory cytokines. In addition, Malassezia spp. induces auto-reactive T cells that 
cross-react between fungal proteins and their human counterparts. These mechanisms 
contribute to skin inflammation in atopic dermatitis and therefore influence the course of 
this disorder. Finally, we discuss the possible benefit of an anti-Malassezia spp. treatment 
in patients with atopic dermatitis. 
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1. Introduction 
Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder. It is characterized 
by intensely itchy skin eczema and is frequently associated with allergic rhino-conjunctivitis and 
allergic asthma. The prevalence of AD in industrialized countries has tripled during the past 30 years [1], 
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affecting 15%–30% of children and up to 10% of adults [2]. Despite its frequency and impact on 
public health, we do not fully understand the pathogenesis of AD. It appears to be in parts genetically 
determined and several factors seem to contribute to the development of AD. For example, the skin of 
AD patients is characterized by an impaired skin barrier function with increased trans-epidermal water 
loss, increased surface pH, reduced stratum corneum hydration and reduced expression of tight 
junction components [3]. Second, the skin immune system in AD patients is altered compared to 
healthy individuals [4]. For example, AD patients have increased levels of the cytokines interleukin 
(IL-) 4, IL-10 and IL-13 in their skin compared to healthy controls. These cytokines reduce the 
production of the antimicrobial peptides LL-37, human beta defensin (hBD)-2, and hBD-3 in 
keratinocytes [5–7], which are important components of the skin’s innate immune system in the 
defense against microorganisms. It can be speculated that the impaired skin barrier function and the 
altered skin immune system may play intertwining roles and contribute to colonization and growth of 
microorganisms on the skin of AD patients [3,7]. The altered skin colonization with microorganisms in 
AD patients versus healthy individuals has been extensively investigated for bacteria, in particular 
Staphylococcus aureus. During recent years, AD research has also focused on the possible 
pathogenetic correlation between eczema and the skin commensal fungus Malassezia spp. because AD 
patients are often sensitized to Malassezia spp.; and AD patients may benefit from an antifungal 
therapy that is effective against Malassezia spp. This led to the publication of a plethora of studies on 
the possible role of Malassezia spp. in the development and course of AD. Here, we will  
review the biology of Malassezia spp. on human skin and the current state of research on the role of  
Malassezia spp. in AD. 
2. Malassezia spp. As Part of the Normal and Atopic Skin Flora 
The skin is an ecosystem and harbors diverse and body site-specific microbial communities, which 
have been termed the skin microbiome. The phylogenetic profiling of the skin microbiome revealed 
that fungi are part of the normal skin flora at all body sites and comprise 1%–22% of the phylogenetic 
composition of the skin microbiome [8]. The fungal flora of the healthy skin almost exclusively 
comprises Malassezia spp., and Malassezia spp. is therefore the main eukaryotic member of the 
microbial flora of the skin [8,9]. Malassezia spp. is a genus of lipophilic yeasts (Figure 1). Most of the 
species within this genus lack the genes for fatty acid synthase genes and therefore rely on exogenous 
fatty acid sources to satisfy their nutritive requirement [10]. M. pachydermatis, a species isolated from 
dogs and other animals [11], is the only known Malassezia species that grows in the absence of 
exogenous lipids [10]. Their need for exogenous lipids explains the predilection of Malassezia species 
for seborrheic skin sites, such as the head and neck. 
The taxonomy of Malassezia spp. has been controversial since its recognition as a member of the 
human skin flora in the mid-19th century. The taxonomy was defined in its current form in 1996, based 
on morphology, ultrastructure, physiology and molecular biology [12]. Malassezia spp. belongs to the 
phylum Basidiomycota and currently encompasses 14 species that have been isolated from human and 
animal skin. Two of these species, M. globosa and M. restricta, predominate on human skin and are 
identified in almost all individuals and body sites [9,13]. Several studies investigated the epidemiology 
of Malassezia spp. in healthy and diseased skin by culture and molecular methods such as polymerase 
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chain reaction [14–23]. These studies obtained variable results presumably owing to methodical 
inconsistencies between the studies; for example, the sampling sites were inconsistent between these 
studies. Next generation sequencing revealed that the skin fungal microbiome is  
highly site specific between body sites [13]. Therefore, comparing the prevalence of Malassezia 
species between different body sites sampled in different studies will give unreliable results. In 
addition, the epidemiological studies used different culture media to detect Malassezia species, and it 
was shown that different culture media favor the growth of particular Malassezia  
species [24,25].Therefore, the use of only one or a few types of culture media does not necessarily 
depict the whole spectrum of Malassezia species present in a sample. Despite these methodical 
considerations, epidemiological studies indicated a geographical variation in the distribution of 
particular Malassezia species, presumably owing to climate factors. For example,  
M. sympodialis has been reported in studies from Canada, Russia and Sweden as the most frequent 
species, whereas in Japan M. furfur was the most common species [14–23]. Of importance, studies 
comparing healthy individuals and AD patients did not reveal a difference in the frequency of skin 
colonization with Malassezia spp. between both groups [14–23]. 
 
Figure 1. Microscopic image of a Malassezia spp. culture. Methylene blue staining. 
3. Sensitization to Malassezia spp. May Correlate with the Severity of Atopic Dermatitis 
Malassezia spp. as part of the healthy skin flora regularly interacts with the skin immune system. 
Therefore Malassezia spp.-specific IgG and IgM antibodies can be detected in healthy individuals [10]. 
However, healthy individuals are usually not sensitized to Malassezia spp., while a high proportion of 
AD patients is sensitized to this yeast [26]. This was demonstrated by positive atopy patch tests, skin 
prick tests or the presence of Malassezia spp.-specific IgE antibodies [26]. For example, 30%–80% of 
adult AD patients have a positive skin prick test with Malassezia spp. extract [27–30]. Unfortunately, 
standardized skin test extracts for Malassezia spp. are not yet commercially available, making it 
difficult to compare the results of different studies. In contrast, Malassezia spp.-specific serum IgE can 
be measured using a commercial and standardized kit (ImmunoCAP® m70, Phadia) based on  
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M. sympodialis (ATCC strain 42,132). Recently, a new kit containing several species of Malassezia 
has been introduced (ImmunoCAP® m227) with a slightly increased sensitivity compared to the single 
species test according to our experience [31]. Using these commercial kits, Malassezia spp.-specific 
IgE are found in 5%–27% of children [27,32–34] and 29%–65% of adults with AD [27,31,34–36], 
which is consistent with the rates found by skin prick tests. Sensitization rates against Malassezia spp. 
are particularly higher in patients with head and neck types of AD [31]. Therefore, some authors 
assume that Malassezia spp. plays a pathogenetic role, particularly in this type of AD [37]. 
The reason for the high frequency of Malassezia spp.-sensitization in AD patients compared to 
healthy individuals is still unclear but is attributed to a combination of dysfunctional skin barrier, 
genetic background, and environmental factors [38]. Several recent studies investigated a possible 
correlation between AD severity and the IgE-mediated sensitization to Malassezia spp. Our group 
analyzed 132 children and 67 adults with AD and found a significant correlation between the severity 
of AD and sensitization to Malassezia spp.-specific IgE in adults but not in children [34]. These results 
substantiated previous findings in 61 adult AD patients from Japan [39]. The lower frequency of 
Malassezia spp. sensitization in children compared to adults and the missing correlation between AD 
severity and Malassezia spp.-specific IgE in children might owe to the poor growth conditions for 
Malassezia spp. in children compared to adults. The lipid content of sebum, which is a prerequisite for 
skin colonization with most Malassezia spp. is low in children but rises during puberty and is high 
until the age of 50 [40]. Accordingly, sensitization to Malassezia spp. seems to occur preferably in 
adulthood, while sensitization to food allergens and aeroallergens frequently occurs during childhood [34]. 
Several allergens of Malassezia spp. elucidate a specific IgE response (Figure 2). To date, 13 allergens 
from two Malassezia species, M. furfur and M. sympodialis, are listed in the official allergen 
nomenclature list (http://www.allergen.org). In vitro experiments confirmed that Malassezia spp. 
release more allergens in the less acidic environment of pH 6.0 that represents conditions of atopic 
skin, than in the more acidic environment of pH 5.5 of healthy skin [41] (Figure 2). However, despite 
the frequent sensitization of adult AD patients against Malassezia spp., it is unclear if the IgE response 
plays a pathogenetic role in AD or rather serves as a marker for the severity of AD. 
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Figure 2. Proposed mechanisms by which Malassezia spp. contributes to skin inflammation 
in atopic dermatitis (AD) patients. The increased pH in atopic skin contributes to increased 
allergen release by Malassezia spp. These allergens, supposedly together with whole 
Malassezia spp. cells, penetrate the epidermis through the disturbed skin barrier in AD 
patients. Malassezia spp. cells and their allergens may be recognized by toll-like receptor 2 
expressed on keratinocytes and dendritic cells which elicits the release of pro-inflammatory 
cytokines. Malassezia spp. components elicit the production of Malassezia spp.-specific 
IgE antibodies through the dendritic cells and T cell-mediated activation of B cells.  
These IgE antibodies may also contribute, possibly through mast cells, to the inflammation 
in atopic skin. Finally, autoreactive T cells can cross react between fungal and human 
manganese-dependent superoxide dismutase (MgSOD) and hence sustain skin inflammation. 
4. Malassezia spp. Interacts with the Skin Immune System 
The interaction between Malassezia spp. and the skin immune system supposedly contributes to 
skin inflammation in AD patients. For example, the Malassezia spp. allergen Mala s 13 is a fungal 
thioredoxin that is very similar to its human homolog. CD4+ T cells that react against the fungal 
thioredoxin of Malassezia spp. are fully cross-reactive to the human enzyme. Therefore, besides 
recognizing the fungal enzyme, these T cells cross-react with the human enzyme, what may contribute 
to skin inflammation in AD [42]. A similar induction of autoreactive T cells was observed for a 
different Malassezia spp. allergen; Mala s 11 is a manganese-dependent superoxide dismutase with a 
high degree of sequence identity to the corresponding human enzyme. Similar to Mala s 13, Mala s 11 
activates T cells that then react against the human homolog and sustain skin inflammation (Figure 2). 
These findings were substantiated by the strong correlation between AD severity and sensitization to 
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Mala s 11 [43]. A protein from M. globosa, MGL_1304, was recently identified in the sweat of  
AD patients and is a potential allergen that may contribute to skin inflammation in AD [44].  
The sensitization to this protein also positively correlates with the severity of AD [45]. 
Prior studies indicated that Malassezia spp. cells interact with various types of human skin and 
immune cells. This induces a pro-inflammatory immune response by the skin and immune cells, which 
may maintain skin inflammation in AD. It is still unclear how this interaction between Malassezia spp. 
cells and host cells occurs, and at least two possible ways of interaction are hypothesized. First,  
the impaired skin barrier facilitates the physical encounter between Malassezia spp. cells and cells of 
the epidermis and dermis, such as keratinocytes, Langerhans cells, dermal dendritic cells, natural killer 
cells and fibroblasts [46]. A second possible mechanism of Malassezia spp.—human cell  
interaction—might be mediated by immunogenic proteins of Malassezia spp. These proteins can be 
released in nanovesicles [47] and it was demonstrated that these proteins that might be present in these 
nanovesicles induce an increased release of TNF-alpha, IL-6, IL-8, IL-10 and IL-12p70 by dendritic 
cells and mast cells [48,49]. Other proteins such as MGL_1304 induce the degranulation of mast cells 
and the release of IL-4 by basophils [44]. 
Some authors suggest that Toll-like receptors (TLRs) mediate the communication between whole 
Malassezia spp. cells or their immunogenic proteins and human cells. TLRs are members of the large 
family of pattern recognition receptors, which play a key role in the innate immune system as they 
recognize molecules that are commonly shared by pathogens. It is known that particularly TLR2 
recognizes components of yeast such as Malassezia spp. [7]. Some recent findings substantiated the 
relevance of TLRs for the immune response of human cells against Malassezia spp. For example, 
Malassezia spp. induces the expression of TLR2 and TLR4 on human keratinocytes [50,51], which 
mediate the increased production of the antimicrobial peptide human beta defensin 2 and the 
chemokine CXLC8 [51]. Others attribute the pro-inflammatory response of dendritic cells against 
Malassezia spp. to TLR-mediated mechanisms [46] (Figure 2). 
The interaction between Malassezia spp. cells and human cells elicits a cytokine release by the 
human cells [3,52,53]. For example, various Malassezia species activate the NLRP3 inflammasome in 
skin dendritic cells and induce the production of IL-1β, IL-4, IL-5, IL-13, and IL-18 [3,52,53]. 
Additionally, mast cells of AD patients release increased amounts of IL-6 in response to M. sympodialis 
exposure [54]. This cytokine release from human cells in response to Malassezia spp. is suggested to 
contribute to the skin inflammation in AD (Figure 2). 
Therapeutic Approaches with Antifungals in AD 
The most effective therapy for AD patients comprises excellent skin care to reconstitute the 
impaired skin barrier, anti-inflammatory treatment most commonly with topical steroids or calcineurin 
inhibitors, and the identification and elimination of trigger factors [38]. The significance of an 
antifungal therapy for AD has been discussed since many years. Azole antifungals are the most 
common class of antifungal drugs prescribed for AD patients. In vitro, azole antifungals are effective 
against Malassezia spp. [55,56] but susceptibility testing of M. pachydermatis, a species most 
commonly isolated from dogs, showed that strains isolated from dogs with AD were less susceptible to 
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azole antifungals than strains isolated from healthy dogs [57]. The relevance of this finding for 
Malassezia isolates from humans remains to be elucidated. 
In a clinical routine, the topical application of ketoconazole on the face of patients with AD of the 
head and neck type frequently improves eczema, presumably due to a partial overlap with seborrhoic 
dermatitis in some cases. However, a placebo-controlled study with topical miconazole-hydrocortisone 
cream and ketoconazole shampoo in AD of the head and neck type did not show any difference to 
treatment with hydrocortisone alone [58]. The effect of topical antifungals alone in AD compared with 
topical steroids or calcineurin inhibitors has not yet been investigated to date. The benefit of a systemic 
antifungal treatment for AD patients has been assessed in several randomized, placebo-controlled 
trials. A study compared 36 AD patients treated with ketoconazole with 39 AD patients treated with 
placebo. AD severity improved significantly in the ketoconazole group but not in the placebo group [59]. 
In another trial, a total of 53 AD patients were treated with either two different dosages of itraconazole 
or placebo. The improvement of AD severity was significantly higher in itraconazole treated patients 
than in the placebo group [60]. These positive effects of antifungals were not confirmed by another 
study comparing 15 AD patients treated with ketoconazole with 14 AD patients treated with placebo. 
Notably, both treatment groups received topical steroids. Although AD severity improved in both 
treatment groups, this improvement was not correlated to ketoconazole but rather to the topical  
steroids [61]. The ambiguous results of these clinical trials might be attributed to a selection bias.  
It can be speculated that antifungal therapies are more effective in one subgroup of AD patients than in 
another, for example in patients with a head-neck type of eczema. More recently published studies 
were of less quality, for example they comprised retrospective observations and lacked a standardized 
scoring system to assess the severity of AD [62]. Such trials are not appropriate to finally decide on a 
positive benefit of antifungal therapy in AD patients. Therefore, more randomized, placebo-controlled 
studies to assess the benefit of antifungal therapy in AD are needed. These studies should be designed 
to determine the subgroup of AD patients that benefits most from an antifungal treatment and to 
determine the optimal treatment regimen. 
Interestingly, azole antifungals such as ketoconazole or itraconazole have anti-inflammatory 
properties. It was shown that these drugs inhibit the production of IL-4 and IL-5 by T cells,  
which might reduce skin inflammation and therefore contribute to improvement of eczema during 
antifungal treatment [63]. 
Another therapeutic approach for AD patients specifically against Malassezia spp. might be 
photodynamic therapy. M. furfur was cultured in the presence of a cationic photosensitizer.  
The irradiation with a 670-nm diode laser significantly reduced the viablity of M. furfur culture, 
depending on irradiation duration and photosensitizer dosage [64]. However, the relevance of these 
results in clinical routine still needs to be proved. 
5. Conclusions 
In summary, there is little doubt that Malassezia spp. plays a role in AD. This yeast may interact 
with the skin immune system, which is facilitated by the impaired barrier function of atopic skin,  
and sensitization against Malassezia spp. correlates with the activity of AD. In addition, antifungal 
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therapy shows beneficial effects in some patients. However, the pathogenetic mechanism and mutual 
interaction between Malassezia and AD still remain partly unclear and need further investigation. 
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